Rhythmia Medical Inc. drummed up $5 million in equity from eight investors, according to a Securities & Exchange Commission filing.
The Burlington, Mass.-based developer of medical devices for treating arrhythmia is still $2 million shy of its $7 million target for this funding round, according to the filing.
The identity of the participants in the latest round were not disclosed, but Waltham, Mass.-based Norwich Ventures has been an active financial supporter of the company. The firm led a $7 million Series B round three years ago and has provided Rhythmia Medical with nearly $12 million in total backing. Rhythmia also raised $2.7 million in a third-round equity sale to a group of 14 investors in March. Since the company was founded in 2004 by two Israeli entrepreneurs it has raised about $22 million in equity funding.
The Mechanics of a More Connected Healthcare Ecosystem [Video]
Arbiter’s Anjali Jameson on hospital and payer alignment.
The company last year also received a pair of Small Business Innovation Research grants from the National Institutes of Health.
The principals named in the most recent filing are co-CEOs and founders Doron Harlev and Leon Amariglio and board members Michael Dale, Norwich Ventures director Philip Fleck and Shraga Katz of Israel-based Magma Venture Partners.
How Artera is Using Agentic AI to Humanize Patient Care
Artera President Tom McIntyre talks about the practical application of AI in healthcare.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.